{
    "organizations": [],
    "uuid": "5c2b2098063e7b8b4e49955f13501bee5877edd0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/mylan-nl-mapi/mylan-buys-marketing-rights-to-ms-treatment-from-israels-mapi-pharma-idUSL3N1RN4GB",
    "ord_in_thread": 0,
    "title": "Mylan buys marketing rights to MS treatment from Israel's Mapi Pharma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10 (Reuters) - Drugmaker Mylan NV is acquiring global marketing rights to an experimental multiple sclerosis treatment from Israelâ€™s Mapi Pharma Ltd, the companies said on Tuesday.\nBoth companies will partner on the development and commercialization of GA Depot, a long-acting injection used once a month, for the treatment of patients with a type of multiple sclerosis. (Reporting by Tamara Mathias in Bengaluru; Editing by Shounak Dasgupta)\n ",
    "published": "2018-04-10T19:47:00.000+03:00",
    "crawled": "2018-04-11T18:09:41.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "drugmaker",
        "mylan",
        "nv",
        "acquiring",
        "global",
        "marketing",
        "right",
        "experimental",
        "multiple",
        "sclerosis",
        "treatment",
        "israel",
        "mapi",
        "pharma",
        "ltd",
        "company",
        "said",
        "tuesday",
        "company",
        "partner",
        "development",
        "commercialization",
        "ga",
        "depot",
        "injection",
        "used",
        "month",
        "treatment",
        "patient",
        "type",
        "multiple",
        "sclerosis",
        "reporting",
        "tamara",
        "mathias",
        "bengaluru",
        "editing",
        "shounak",
        "dasgupta"
    ]
}